anti tirzepatide antibody reaction Pharmacogenomics of Tirzepatide: Genomic Insights into Dual GIP/GLP-1 Agonist Response in Type 2 Diabetes and Atherosclerosis tirzepatide antibodies anti Technological advancements

Lower Blood Pressure Semaglutide has been shown to reduce systolic blood pressure, which is essential for cardiovascular health

That is the heart of functional medicine: the protocol fits the patient, not the other way around

This supports a shift from fat storage toward fat burning

In this webinar, youll learn about benefits, side effects, real patient stories, and how our care team can support you every step of the way if you decide to give treatment a try

For patients without established atherosclerotic CV disease (ASCVD) or chronic kidney disease (CKD) and for whom there is a compelling need to minimize weight gain or promote weight loss, the American Diabetes Association (ADA) and European Association for the Study of Diabetes (EASD) guidelines recommend GLP-1RA and sodium-glucose co-transporter-2 inhibitor (SGLT2i) drugs as the preferred second-line treatment option for patients with inadequate glycemic control despite use of metformin [1, 9]

We've seen what works and what doesn't